Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

CAR T-Cell Therapy KTE-C19 Shows Promise in Non-Hodgkin Lymphoma

December 22nd 2015

Frederick Locke, MD, discusses the potential for KTE-C19 in non-Hodgkin lymphoma.

Frontline Brentuximab Vedotin Generates 76% Complete Remission Rate in DLBCL

December 22nd 2015

Adding brentuximab vedotin (Adcetris) to frontline R-CHOP produced a greater than 80% response rate—including complete remissions in three-fourths of patients—as a treatment for CD30+ diffuse large B-cell lymphoma.

Dr. Sharman on Entospletinib in Patients With CLL

December 18th 2015

Jeff Sharman, MD, director of Research with Willamette Valley Cancer Institute and Research Center, medical director of Hematology Research for The US Oncology Network, discusses clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.

Dr. Vlock on Anti—CD20 Interleukin-2 Immunocytokine in NHL

December 14th 2015

Daniel R. Vlock, MD, founder and CEO, Alopexx Pharmaceuticals, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

FDA Approves Bendamustine Hydrochloride for CLL, NHL

December 9th 2015

The FDA has approved a rapid infusion formulation of bendamustine under the trade name Bendeka for the treatment of patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Dr. Kipps on Ibrutinib Versus Chlorambucil in Treatment-Naïve CLL/SLL

December 8th 2015

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Ibrutinib Active in Rituximab-Refractory WM

December 7th 2015

More than 80% of patients with treatment-refractory Waldenstrom's macroglobulinemia responded to single-agent therapy with ibrutinib, according to results of a preliminary clinical trial.

High Response Rates Seen With CAR T-Cell Therapies for NHL

December 7th 2015

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Goy on Going Beyond R-CHOP in Large-Cell Lymphoma

November 19th 2015

Dr. Andre Goy discusses combining novel agents with R-CHOP for the treatment of large-cell lymphoma.

Dr. Leonard on Treatment Options for Patients With Indolent B-Cell NHL

November 16th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses therapies available for patients with indolent B-cell Non-Hodgkin lymphoma.

Genetics Should Dictate Treatment for Waldenström's Macroglobulinemia

November 3rd 2015

Mutations in MYD88 and CXCR4 can effectively be used to tailor treatment for patients with Waldenström's macroglobulinemia.

Radiation Underutilized in Low-Grade Follicular Lymphoma

October 22nd 2015

The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.

Dr. Shpall on Therapeutic Agents for the Treatment of CLL

October 20th 2015

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Combination Therapy the Future for Mantle Cell Lymphoma

September 24th 2015

The heterogeneity of mantle cell lymphoma will require new combination strategies to improve outcomes.

Progress Toward Reducing Failure in Follicular Lymphoma

September 24th 2015

Lack of improvement in failure-free survival for patients with follicular lymphoma has fueled interest in new treatment strategies that might offer promise of better outcomes.

High-Risk Follicular Lymphoma Subgroup Identified

August 24th 2015

Patients with follicular lymphoma progressing within 2 years on first-line R-CHOP have a 5-year overall survival rate of only 50%, compared with 90% in longer responders.

Obinutuzumab's Benefit in iNHL Unclear After GAUSS Results Published

August 24th 2015

The anti-CD20 agent obinutuzumab improved overall response and had acceptable toxicity compared with rituximab in patients with relapsed indolent non-Hodgkin Lymphoma, according to the final results from the GAUSS study.

Dr. Leonard on Ibrutinib Combined With Chemotherapy in Follicular Lymphoma

August 20th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the phase III SELENE study, which is examining the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma.

Ibrutinib Induces Impressive Response in DLBCL Subtype

July 30th 2015

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

Gender Disparities and Other DLBCL Developments

July 28th 2015

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.

NEXT PAGE
PREVIOUS PAGE